SCHEDULE: Bayer Maintains 17.82% Stake in Senti Biosciences
Schedule 13D Amendment
Bayer HealthCare LLC and associated entities filed an amended Schedule 13D confirming a 17.82% beneficial ownership stake in Senti Biosciences, Inc.
Summary
- Bayer HealthCare LLC, Bayer US Holding LLC, Sebastian Guth, and Priyal Patel collectively report beneficial ownership of 6,142,848 shares of Senti Biosciences common stock.
- The reported stake represents 17.82% of the issuer's outstanding common stock.
- The ownership figure includes 3,333,000 shares issuable upon the exercise of warrants that are exercisable within 60 days.
- The calculation is based on 31,144,497 shares of common stock outstanding as of March 19, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative update confirming existing ownership levels without signaling new capital activity or strategic shifts.
Positives
- Continued strategic alignment and significant equity investment from a major industry player like Bayer.
- The inclusion of warrants exercisable within 60 days indicates potential for increased equity participation.
Negatives
- The reporting persons disclaim beneficial ownership of shares other than those owned of record, highlighting a complex ownership structure.
Risks
- Concentration of ownership by a single major shareholder could influence corporate decision-making.
- Reliance on warrant exercise for a significant portion of the reported beneficial ownership.
Future Outlook
The filing does not provide specific forward-looking guidance regarding the issuer's operations, but confirms the continued holding of warrants and equity by the reporting persons.
Management Comments
- The reporting persons certify that the information set forth in the statement is true, complete, and correct.
Industry Context
StockSavvy.ai notes that this filing reflects the ongoing trend of large pharmaceutical companies maintaining strategic equity positions in emerging biotech firms to secure access to innovative gene and cell therapy platforms.
Comparison to Industry Standards
- The 17.82% stake is consistent with strategic minority investments seen in the biotech sector where large-cap pharma partners with clinical-stage developers.
- The use of warrants as part of the ownership structure is a standard mechanism in private placement and PIPE transactions within the life sciences industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Appointment of Nicholas Massey as attorney-in-fact for Priyal Patel. | 2026-04-15 | Administrative change to facilitate SEC filings. |
Stakeholder Impact
- Shareholders may view the continued significant stake by Bayer as a vote of confidence in the company's long-term technology platform.
Next Steps
- Continued monitoring of potential warrant exercise by Bayer HealthCare LLC.
- Future filings if ownership percentage changes by 1% or more.
Key Dates
| Date | Description |
|---|---|
| 2024-12-02 | Original Securities Purchase Agreement and warrant issuance. |
| 2025-03-17 | Initial Schedule 13D filing date. |
| 2025-12-31 | End of fiscal year for the issuer's 10-K report. |
| 2026-03-19 | Date of outstanding share count used for calculation. |
| 2026-03-27 | Date of event requiring filing and filing of 10-K. |
| 2026-04-15 | Execution of Power of Attorney. |
| 2026-04-16 | Signature date of the Schedule 13D amendment. |
Keywords
Senti Biosciences, Bayer HealthCare, Schedule 13D, Beneficial Ownership, Biotech, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.